Exact Sciences (EXAS) Stock Price, News & Analysis

Company Overview

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of cancer. Founded in 1995 and headquartered in Madison, Wisconsin, the company developed Cologuard, the first noninvasive, stool-based DNA screening test for colorectal cancer approved by the U.S. Food and Drug Administration. Cologuard combines DNA and hemoglobin biomarkers to detect cancerous and precancerous lesions, offering an alternative to traditional colonoscopy for average-risk patients.

In addition to its flagship colorectal cancer test, Exact Sciences has expanded its portfolio through strategic acquisitions and internal research. The acquisition of Genomic Health in 2019 extended the company’s precision oncology offerings by bringing Oncotype DX tests for breast, prostate and other cancers under its umbrella. These genomic assays analyze tumor biology to guide treatment decisions, helping oncologists personalize therapy and avoid unnecessary treatments.

Exact Sciences serves patients and healthcare providers across the United States and has begun international expansion into Europe, Canada and select Latin American markets. The company works closely with health systems, payers and advocacy organizations to increase adoption of its tests and integrate digital solutions for patient education and physician reporting. By building partnerships with research institutions, Exact Sciences also seeks to identify novel biomarkers and develop next-generation screening technologies.

Under the leadership of President and CEO Kevin Conroy, Exact Sciences has emphasized a collaborative culture that unites diagnostics, research and commercial expertise. The management team includes executives with backgrounds in biotechnology, genomics and health economics, driving efforts to improve screening rates and advance the company’s pipeline of liquid biopsy tests for multiple cancer types. Exact Sciences continues to invest in innovation and scale its operations with the goal of transforming cancer detection and patient outcomes worldwide.

Key Stats

• Today's Range: $52.76 to $54.85
• 50-Day Range: $51.17 to $58.08
• 52-Week Range: $39.97 to $72.83
• Volume: 2.62 million shs
• Average Volume: 2.58 million shs
• Market Capitalization: $10.00 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.50
• Consensus Rating: Moderate Buy

Exact Sciences Stock Analysis - MarketRank™

Exact Sciences scored higher than 94% of companies evaluated by MarketBeat, and ranked 63rd out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Exact Sciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.95, and is based on 19 buy ratings, 2 hold ratings, and no sell ratings.

Amount of Analyst Coverage

Exact Sciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Exact Sciences are expected to grow in the coming year, from ($0.58) to $0.50 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Exact Sciences is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Exact Sciences is -9.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Growth Ratio

Exact Sciences has a PEG Ratio of 11.08. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Exact Sciences has a P/B Ratio of 4.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.77% of the float of Exact Sciences has been sold short.

Short Interest Ratio / Days to Cover

Exact Sciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exact Sciences has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Exact Sciences does not currently pay a dividend.

Dividend Growth

Exact Sciences does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.7 / 5
• Environmental Score: -0.83

Percentage of Shares Shorted

3.77% of the float of Exact Sciences has been sold short.

Short Interest Ratio / Days to Cover

Exact Sciences has a short interest ratio ("days to cover") of 2.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Exact Sciences has recently decreased by 11.48%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: 0.86

News Sentiment

Exact Sciences has a news sentiment score of 0.86. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Exact Sciences this week, compared to 11 articles on an average week.

Search Interest

9 people have searched for EXAS on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.

MarketBeat Follows

2 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Exact Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $170,612.00 in company stock.

Percentage Held by Insiders

Only 1.20% of the stock of Exact Sciences is held by insiders.

Percentage Held by Institutions

88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

EXAS Stock Analysis - Frequently Asked Questions

How have EXAS shares performed this year?

Exact Sciences' stock was trading at $56.19 at the beginning of the year. Since then, EXAS shares have decreased by 5.7% and is now trading at $52.99.

How were Exact Sciences' earnings last quarter?

Exact Sciences Corporation (NASDAQ:EXAS) released its earnings results on Thursday, May, 1st. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.16. Exact Sciences's quarterly revenue was up 10.9% compared to the same quarter last year.
Read the conference call transcript.

Does Exact Sciences have any subsidiaries?

The following companies are subsidiaries of Exact Sciences: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more.

Who are Exact Sciences' major shareholders?

Exact Sciences' top institutional investors include Zevenbergen Capital Investments LLC (0.54%), Kingstone Capital Partners Texas LLC (0.15%), Public Employees Retirement System of Ohio (0.03%) and Harbor Capital Advisors Inc. (0.03%). Insiders that own company stock include Kevin T Conroy, Katherine S Zanotti, Sarah Condella, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott.
View institutional ownership trends.

How do I buy shares of Exact Sciences?

Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Exact Sciences own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), CrowdStrike (CRWD), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/15/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:EXAS
• CIK: 1124140
• Web: www.exactsciences.com
• Phone: (608) 284-5700
• Fax: 608-284-5701
• Employees: 7,000
• Year Founded: 1995

Price Target and Rating

• Average Price Target for Exact Sciences: $70.50
• High Price Target: $90.00
• Low Price Target: $54.00
• Potential Upside/Downside: +32.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.95
• Research Coverage: 22 Analysts

Profitability

• EPS (Trailing Twelve Months): ($5.51)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: 11.08
• Net Income: -$1.03 billion
• Net Margins: -36.06%
• Pretax Margin: -36.38%
• Return on Equity: -3.75%
• Return on Assets: -1.68%

Debt

• Debt-to-Equity Ratio: 0.97
• Current Ratio: 2.73
• Quick Ratio: 2.38

Sales & Book Value

• Annual Sales: $2.76 billion
• Price / Sales: 3.64
• Cash Flow: $5.78 per share
• Price / Cash Flow: 9.22
• Book Value: $12.98 per share
• Price / Book: 4.11

Miscellaneous

• Outstanding Shares: 188,640,000
• Free Float: 186,374,000
• Market Cap: $10.06 billion
• Optionable: Optionable
• Beta: 0.95